See more : Fujian Longking Co., Ltd. (600388.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Novogene Co., Ltd. (688315.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novogene Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Zhejiang Shibao Company Limited (1057.HK) Income Statement Analysis – Financial Results
- Hydrofarm Holdings Group, Inc. (HYFM) Income Statement Analysis – Financial Results
- Fukuyama Transporting Co., Ltd. (9075.T) Income Statement Analysis – Financial Results
- Walkabout Resources Limited (WKT.AX) Income Statement Analysis – Financial Results
- Basetrophy Group Holdings Limited (8460.HK) Income Statement Analysis – Financial Results
Novogene Co., Ltd. (688315.SS)
About Novogene Co., Ltd.
Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus, a next-generation sequencing based companion diagnostic assay for PARP inhibitor therapies; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples. Novogene Co., Ltd. has a strategic partnership with Hummingbird Bioscience Pte. Ltd. to support the development of investigational drug candidate HMBD-001, an anti-HER3 antibody to be evaluated for treatment of various tumor types, including NRG1-fusion driven cancers. The company was founded in 2011 and is headquartered in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.00B | 1.93B | 1.87B | 1.49B | 1.53B | 1.05B | 739.35M | 458.47M | 309.83M |
| Cost of Revenue | 1.15B | 1.07B | 1.07B | 966.68M | 933.89M | 601.74M | 422.87M | 238.41M | 147.53M |
| Gross Profit | 855.55M | 852.68M | 800.47M | 523.35M | 600.94M | 451.83M | 316.48M | 220.06M | 162.29M |
| Gross Profit Ratio | 42.73% | 44.28% | 42.89% | 35.12% | 39.15% | 42.89% | 42.81% | 48.00% | 52.38% |
| Research & Development | 124.18M | 125.57M | 145.29M | 112.31M | 125.71M | 79.42M | 50.36M | 30.53M | 45.46M |
| General & Administrative | 23.27M | 32.36M | 29.71M | 24.61M | 35.86M | 23.14M | 15.50M | 50.84M | 36.35M |
| Selling & Marketing | 102.72M | 331.64M | 274.41M | 235.55M | 229.81M | 155.95M | 123.67M | 89.20M | 49.90M |
| SG&A | 125.99M | 364.00M | 304.12M | 260.15M | 265.67M | 179.08M | 139.17M | 140.04M | 86.25M |
| Other Expenses | 390.50M | 119.87M | 94.22M | 86.68M | 77.45M | -25.95K | -22.17K | 5.26M | 3.16M |
| Operating Expenses | 640.67M | 609.44M | 543.62M | 459.15M | 468.82M | 338.52M | 252.08M | 172.08M | 131.82M |
| Cost & Expenses | 1.79B | 1.68B | 1.61B | 1.43B | 1.40B | 940.25M | 674.95M | 410.49M | 279.35M |
| Interest Income | 5.19M | 1.54M | 1.74M | 335.72K | 1.17M | 704.83K | 2.93M | 438.47K | 275.02K |
| Interest Expense | 3.54M | 2.15M | 2.92M | 10.27M | 2.68M | 557.23K | 1.85M | 888.07K | 1.31M |
| Depreciation & Amortization | 152.46M | 137.77M | 136.67M | 110.48M | 91.63M | 85.78M | 55.40M | 27.46M | 11.61M |
| EBITDA | 369.41M | 343.02M | 387.78M | 157.93M | 214.49M | 199.67M | 146.90M | 78.16M | 50.27M |
| EBITDA Ratio | 18.45% | 20.42% | 20.79% | 11.02% | 14.47% | 19.08% | 19.28% | 16.54% | 15.07% |
| Operating Income | 214.88M | 212.45M | 246.49M | 58.57M | 119.27M | 112.90M | 88.88M | 44.33M | 30.44M |
| Operating Income Ratio | 10.73% | 11.03% | 13.21% | 3.93% | 7.77% | 10.72% | 12.02% | 9.67% | 9.83% |
| Total Other Income/Expenses | -2.25M | -3.90M | 150.31K | -23.04M | -60.07K | -25.95K | 34.13M | 5.26M | 3.16M |
| Income Before Tax | 212.63M | 208.56M | 246.46M | 35.53M | 119.21M | 112.87M | 88.86M | 49.59M | 33.60M |
| Income Before Tax Ratio | 10.62% | 10.83% | 13.21% | 2.38% | 7.77% | 10.71% | 12.02% | 10.82% | 10.85% |
| Income Tax Expense | 29.41M | 27.02M | 17.80M | 1.09M | 4.78M | 15.00M | 7.81M | 10.48M | 8.81M |
| Net Income | 178.06M | 177.23M | 225.20M | 36.54M | 114.29M | 97.10M | 80.50M | 39.13M | 24.79M |
| Net Income Ratio | 8.89% | 9.20% | 12.07% | 2.45% | 7.45% | 9.22% | 10.89% | 8.54% | 8.00% |
| EPS | 0.44 | 0.44 | 0.56 | 0.09 | 0.29 | 0.27 | 0.22 | 0.34 | 0.06 |
| EPS Diluted | 0.44 | 0.44 | 0.56 | 0.09 | 0.29 | 0.27 | 0.22 | 0.34 | 0.06 |
| Weighted Avg Shares Out | 404.68M | 400.20M | 400.20M | 400.20M | 400.20M | 359.62M | 365.92M | 115.09M | 400.20M |
| Weighted Avg Shares Out (Dil) | 404.68M | 400.20M | 400.20M | 400.20M | 400.20M | 359.62M | 365.92M | 115.09M | 400.20M |
Source: https://incomestatements.info
Category: Stock Reports